Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Vall d'Hebron Institute of Oncology
This program has been made available online.
Downloadable slideset with highlights from key gastrointestinal cancers as presented at 2022 ESMO World Congress on Gastrointestinal Cancer, from Clinical Care Options (CCO)
Expert commentary on potential clinical implications of findings from the MOUNTAINEER trial with tucatinib and trastuzumab in HER2 positive metastatic colorectal cancer, from Clinical Care Options (CCO)
Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)
Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)